SAB Biotherapeutics (NASDAQ:SABS) Downgraded to Strong Sell Rating by Zacks Research

SAB Biotherapeutics (NASDAQ:SABS) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other analysts have also recently issued reports on SABS. Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Chardan Capital increased their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright reduced their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday. Finally, UBS Group assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.00.

SAB Biotherapeutics Stock Down 9.6%

Shares of SABS opened at $4.15 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 9.46. The company has a 50-day simple moving average of $4.02 and a 200-day simple moving average of $3.36. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60. The firm has a market capitalization of $211.44 million, a P/E ratio of -1.79 and a beta of 0.59.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, equities research analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

Several hedge funds have recently modified their holdings of SABS. Perceptive Advisors LLC bought a new position in SAB Biotherapeutics in the 4th quarter worth approximately $3,004,000. Millennium Management LLC bought a new position in SAB Biotherapeutics in the 4th quarter valued at $1,212,000. Balyasny Asset Management L.P. bought a new position in SAB Biotherapeutics in the 4th quarter valued at $1,778,000. ADAR1 Capital Management LLC increased its stake in shares of SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after buying an additional 11,344 shares during the period. Finally, ExodusPoint Capital Management LP bought a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $322,000. 7.82% of the stock is owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.